How to unlock opportunity, manage risk, and make smarter decisions as the axis of the world’s pharma innovation shifts
China’s pharma innovation engine is reshaping the global pharmaceutical landscape. Thousands of new assets, rapid clinical execution, competitive pricing, and deep scientific investment are creating opportunities to strengthen pipelines, offset exclusivity losses, and expand into high-value therapeutic areas.
In this playbook, Evaluate’s pharma experts help you understand the forces driving China’s rise, identify where innovation is attracting global capital, and develop practical strategies for evaluating China-originated assets with confidence.
What you’ll find inside
- A decade of transformation. How government reform, returning scientific talent, and targeted investment propelled China from generic manufacturing to global innovation leadership.
- Where the innovation is strongest. The modalities in which China now leads development; bispecific antibodies, ADCs, CAR-T therapies, and GLP-1s, and what this means for global competition and deal activity.
- Real-world dealmaking momentum. Examples of major Western companies acquiring or partnering with Chinese innovators, and how these deals reflect a broader shift in market confidence.
- How to assess and validate China-originated assets. Practical guidance on due diligence, clinical data review, patent considerations, and risk factors that shape asset valuation.
- Strategic recommendations. How organizations are using evidence-based frameworks and connected data to identify high-potential assets, reduce uncertainty, and execute deals efficiently.
Download Navigating China’s Rise for the strategic context, analytical direction, and practical frameworks you need to make well-informed decisions in a fast-evolving environment.
